Hafnia Limited Common Shares vs uniQure N.V. Ordinary Shares — how do they compare? Hafnia Limited Common Shares trades at $10.2 (market cap $5.76B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Hafnia Limited Common Shares is far larger — about 3.9× uniQure N.V. Ordinary Shares's market cap, and Hafnia Limited Common Shares pays a 10.24% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hafnia Limited Common Shares for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| HAFN | QURE | |
|---|---|---|
Market Cap | $5.76B | $1.48B |
Volume | 1,835,725 | 2,488,780 |
Sector | Industrials | Health |
52-Week High | $10.92 | $70.59 |
52-Week Low | $5.21 | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.37B | $728.62M |
Dividend Yield | 10.24% | — |
Signals from Pluang's Aura AI — not financial advice
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →